Apogee Therapeutics, Inc. (APGE) Research

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

Market snapshot

Symbol
APGE
Price
$90.38
Day change
+2.21%
Market cap
$5.6B
P/E ratio
-22.93x
52-week range
34.34-95.315
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$113.67

Recent news

  • Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program

    Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.

  • Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

    The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.

  • How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug

    Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, Dupixent.

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Celcuity Inc. (CELC)
  • CG Oncology, Inc. Common stock (CGON)
  • Centessa Pharmaceuticals plc (CNTA)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Soleno Therapeutics, Inc. (SLNO)

Recent insider activity

  • HENDERSON MICHAEL THOMAS — S-Sale (6770 shares) on 2026-06-10
  • HENDERSON MICHAEL THOMAS — S-Sale (7654 shares) on 2026-06-10
  • HENDERSON MICHAEL THOMAS — S-Sale (1080 shares) on 2026-06-10
  • HENDERSON MICHAEL THOMAS — S-Sale (1577 shares) on 2026-06-10
  • HENDERSON MICHAEL THOMAS — S-Sale (2305 shares) on 2026-06-10

Open Apogee Therapeutics, Inc. (APGE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.